Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
Identifying Biomarkers for Early Detection of Pancreatic Cancer
A clinical trial for at-risk people is looking for biomarkers that can indicate pancreatic cancer is growing.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
Searching for Potential Pancreatic Cancer Blood Biomarkers
Researchers are using blood samples to follow people considered at-risk for developing pancreatic cancer in a trial looking for early detection biomarkers.
Early Detection Trial for People at Higher Risk of Pancreatic Cancer
Relatives of pancreatic cancer patients or people who carry certain mutations can participate in an early detection clinical trial.
Trying Targeted Treatments Used for Other Cancers
Researchers are trying kinase inhibitors that are effective for breast cancer, colorectal cancer, and melanoma on pancreatic cancer.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.